Genomic Health Newswire

Genomic Health Newswire

Comprehensive Real-Time News Feed for Genomic Health.

Results 1 - 20 of 203 in Genomic Health

  1. Genomic Health, Inc. (GHDX) Receives Consensus Rating of "Hold" from AnalystsRead the original story w/Photo

    18 hrs ago | AmericanBankingNews.com

    Shares of Genomic Health, Inc. have earned a consensus recommendation of "Hold" from the nine brokerages that are presently covering the firm. Two analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company.

    Comment?

  2. Insider Selling: Genomic Health, Inc. (GHDX) Insider Sells 5,000 Shares of StockRead the original story w/Photo

    Friday Mar 24 | AmericanBankingNews.com

    Genomic Health, Inc. insider Steven Shak sold 5,000 shares of the company's stock in a transaction on Thursday, March 23rd. The shares were sold at an average price of $31.26, for a total transaction of $156,300.00.

    Comment?

  3. Published Outcomes Results from SEER Registries Indicates That Many...Read the original story

    Friday Mar 24 | PressReleasePoint

    Genomic Health, Inc. today announced the publication of results from the National Cancer Institute's Surveillance, Epidemiology, and End Results Registry in the peer-reviewed journal Breast Cancer Research and Treatment , reconfirming the value of the Oncotype DX Breast Recurrence ScoreA in guiding chemotherapy treatment decisions in certain node-positive patients . Consistent with previously published findings in Nature Partner Journals Breast Cancer , the new SEER Registries analysis demonstrates that breast cancer patients with limited node-positive disease who have low Breast Recurrence Scorea results have an excellent chance of breast cancer-specific survival .

    Comment?

  4. Laura Leber Sells 3,072 Shares of Genomic Health, Inc. (GHDX) StockRead the original story w/Photo

    Friday Mar 24 | Daily Political

    Genomic Health, Inc. insider Laura Leber sold 3,072 shares of the business's stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $31.88, for a total value of $97,935.36.

    Comment?

  5. Genomic Health Release: Published Outcomes Results From SEER...Read the original story

    Thursday Mar 23 | BioSpace

    Genomic Health Release: Published Outcomes Results From SEER Registries Indicates That Many Node-Positive Breast Cancer Patients Can Avoid Chemotherapy Based On Oncotype DX Results /PRNewswire/ -- Genomic Health, Inc. today announced the publication of results from the National Cancer Institute's Surveillance, Epidemiology, and End Results Registry in the peer-reviewed journal Breast Cancer Research and Treatment , reconfirming the value of the Oncotype DX Breast Recurrence ScoreA in guiding chemotherapy treatment decisions in certain node-positive patients .

    Comment?

  6. Multiple Presentations at 15th St. Gallen International Breast Cancer ...Read the original story

    Monday Mar 20 | PressReleasePoint

    Genomic Health, Inc. today announced results from 15 Oncotype DX Breast Recurrence ScoreA studies conducted in 12 countries that provide real-world evidence of the test's ability to change treatment decisions in breast cancer patients. The new findings, presented at the 15thSt.

    Comment?

  7. Genomic Health Unveils A Wealth Of Data For The Oncotype DX Breast...Read the original story

    Thursday Mar 16 | BioSpace

    Genomic Health Unveils A Wealth Of Data For The Oncotype DX Breast Cancer Test, Reinforcing Its Value In Improving Patient Outcomes And Leading To More Cost-Effective Management a 15 featured abstracts at the 15th St Gallen International Breast Cancer Conference underscore the growing adoption of the company's cutting-edge genomic test to identify those patients who will benefit from chemotherapy after breast cancer surgery a New real world evidence highlights the significant impact in reducing the burden of unnecessary chemotherapy for patients and its associated costs for healthcare systems a Additional data solidify utility of Oncotype DX in patients with node-positive disease Geneva, Switzerland, March 17, 2017 / B3C newswire / -- Genomic Health today announced the presentation of 15 abstracts for the Oncotype DXA breast cancer test at the 15th St Gallen International Breast Cancer ... (more)

    Comment?

  8. Genomic Health Unveils a Wealth of Data for the Oncotype DXA Breast...Read the original story

    Friday Mar 17 | B3C

    ... and its associated costs for healthcare systems Geneva, Switzerland, March 17, 2017 / B3C newswire / -- Genomic Health today announced the presentation of 15 abstracts for the Oncotype DXA breast cancer test at the 15th St Gallen International ...

    Comment?

  9. Camber Capital Management LLC Maintains Position in Genomic Health, Inc.Read the original story

    Thursday Mar 16 | IntersportsWire

    Camber Capital Management LLC continued to hold its stake in shares of Genomic Health, Inc. during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission . The fund owned 2,458,100 shares of the company's stock at the end of the fourth quarter.

    Comment?

  10. Genomic Health, Inc. (GHDX) Stake Boosted by Renaissance Technologies LLCRead the original story w/Photo

    Sunday Mar 12 | Daily Political

    Renaissance Technologies LLC boosted its position in Genomic Health, Inc. by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 576,700 shares of the company's stock after buying an additional 29,100 shares during the period.

    Comment?

  11. Genomic Health, Inc. (GHDX) Insider Kimberly J. Popovits Sells 5,000 SharesRead the original story w/Photo

    Wednesday Mar 8 | IntersportsWire

    Genomic Health, Inc. insider Kimberly J. Popovits sold 5,000 shares of the company's stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $31.09, for a total transaction of $155,450.00.

    Comment?

  12. Kimberly J. Popovits Sells 5,000 Shares of Genomic Health, Inc. (GHDX) StockRead the original story w/Photo

    Tuesday Mar 7 | AmericanBankingNews.com

    Genomic Health, Inc. insider Kimberly J. Popovits sold 5,000 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $31.09, for a total transaction of $155,450.00.

    Comment?

  13. The Best Bet in the Growing Genetic Testing Market: Genetic Health vs. InvitaeRead the original story w/Photo

    Tuesday Mar 7 | The Motley Fool

    ... use a form of genomic analysis to provide cancer-specific information about a tumor (aka the "oncotype"). Genomic Health then uses this information to predict the likelihood of cancer occurrence or recurrence following treatment. 2016 was a strong ...

    Comment?

  14. TheStreet Upgrades Genomic Health, Inc. (GHDX) to C-Read the original story w/Photo

    Friday Mar 3 | IntersportsWire

    Several other brokerages have also recently weighed in on GHDX. Zacks Investment Research cut Genomic Health from a hold rating to a sell rating in a report on Monday, February 6th.

    Comment?

  15. Genomic Health, Inc. (GHDX) Stake Lowered by Two Sigma Investments LPRead the original story w/Photo

    Thursday Mar 2 | IntersportsWire

    Two Sigma Investments LP cut its stake in Genomic Health, Inc. by 10.6% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 205,834 shares of the company's stock after selling 24,408 shares during the period.

    Comment?

  16. Genomic Health, Inc. (GHDX) Upgraded to C- at TheStreetRead the original story w/Photo

    Wednesday Mar 1 | Daily Political

    Other research analysts have also issued reports about the stock. Canaccord Genuity set a $38.00 price target on shares of Genomic Health and gave the company a buy rating in a research note on Monday, January 23rd.

    Comment?

  17. Genomic Health, Inc. (GHDX) Upgraded to "C-" by TheStreetRead the original story w/Photo

    Wednesday Mar 1 | AmericanBankingNews.com

    Several other research analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Genomic Health from a "strong sell" rating to a "hold" rating in a research report on Thursday, February 16th.

    Comment?

  18. Q1 2017 Earnings Estimate for Genomic Health, Inc. (GHDX) Issued By Jefferies GroupRead the original story w/Photo

    Wednesday Mar 1 | IntersportsWire

    Genomic Health, Inc. - Equities researchers at Jefferies Group decreased their Q1 2017 EPS estimates for Genomic Health in a report released on Thursday. Jefferies Group analyst B. Couillard now anticipates that the firm will post earnings of per share for the quarter, down from their prior estimate of $0.01.

    Comment?

  19. Capstone Investment Advisors LLC Takes Position in Genomic Health, Inc.Read the original story w/Photo

    Monday Feb 27 | Daily Political

    Capstone Investment Advisors LLC acquired a new stake in shares of Genomic Health, Inc. during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 11,797 shares of the company's stock, valued at approximately $346,000.

    Comment?

  20. Jefferies Group Research Analysts Decrease Earnings Estimates for Genomic Health, Inc.Read the original story w/Photo

    Sunday Feb 26 | IntersportsWire

    Genomic Health, Inc. - Investment analysts at Jefferies Group reduced their FY2017 earnings per share estimates for shares of Genomic Health in a note issued to investors on Thursday. Jefferies Group analyst B. Couillard now expects that the brokerage will earn $0.03 per share for the year, down from their prior forecast of $0.05.

    Comment?